Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial

What is it about?

Intra-lymphatic administration of GAD-alum is a simple, well-tolerated treatment that has no efficacy in a general T1D population, but seems to preserve C-peptide in the considerable proportion of patients with recent onset T1D carrying HLA DR3-DQ2. This constitutes one of the first disease modifying treatments for T1D with a precision medicine approach.

Featured Image